These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 6252800

  • 21. [Cyclic nucleotides and blood platelet functions].
    Kuramoto A.
    Nihon Rinsho; 1978 Dec 10; 36(12):3813-8. PubMed ID: 34743
    [No Abstract] [Full Text] [Related]

  • 22. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B, Arnout J, Deckmyn H, Vermylen J.
    Thromb Haemost; 1993 Nov 15; 70(5):822-5. PubMed ID: 8128441
    [Abstract] [Full Text] [Related]

  • 23. [The adenylate cyclase system of human platelets].
    Ferry N, Adnot S, Insel PA, Hanoune J.
    Nouv Rev Fr Hematol (1978); 1983 Nov 15; 25(6):343-53. PubMed ID: 6141550
    [Abstract] [Full Text] [Related]

  • 24. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I, Suzuki T.
    J Cyclic Nucleotide Protein Phosphor Res; 1983 Nov 15; 9(4-5):341-53. PubMed ID: 6147364
    [Abstract] [Full Text] [Related]

  • 25. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR, Hatzelmann A.
    Cell Signal; 2005 Mar 15; 17(3):331-9. PubMed ID: 15567064
    [Abstract] [Full Text] [Related]

  • 26. Platelet aggregation and cyclic nucleotide phosphodiesterase activity in arteriosclerotic patients.
    Yamazaki H, Motomiya T, Mashimo N, Asano T, Hidaka H.
    Thromb Haemost; 1978 Feb 28; 39(1):158-66. PubMed ID: 205971
    [Abstract] [Full Text] [Related]

  • 27. Adenylate cyclase and phosphodiesterase activity in the platelet release abnormality.
    Chesney CM, Baker AS, Carvalho AC, Ozer A, Meissner GF, Colman RW.
    Thromb Haemost; 1977 Dec 15; 38(4):971-83. PubMed ID: 203056
    [Abstract] [Full Text] [Related]

  • 28. [Effect of trapidil and papaverine on thrombocyte aggregation and phosphodiesterase activity].
    Glusa E.
    Farmakol Toksikol; 1986 Dec 15; 49(6):48-9. PubMed ID: 3028860
    [Abstract] [Full Text] [Related]

  • 29. The effects of in vitro and in vivo exposure to insulin upon prostaglandin E1 stimulation of platelet adenylate cyclase activity in healthy subjects.
    Jap TS, Kwok CF, Wong MC, Chiang H.
    Diabetes Res; 1994 Dec 15; 27(1):39-46. PubMed ID: 7648795
    [Abstract] [Full Text] [Related]

  • 30. Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors.
    Asano T, Ochiai Y, Hidaka H.
    Mol Pharmacol; 1977 May 15; 13(3):400-6. PubMed ID: 195193
    [No Abstract] [Full Text] [Related]

  • 31. [Changes in the guanylate cyclase activity of human thrombocytes during ADP-inducible aggregation].
    Chirkov IuIu, Belushkina NN, Tyshchuk IA, Severina IS.
    Biull Eksp Biol Med; 1991 Feb 15; 111(2):152-4. PubMed ID: 1677293
    [Abstract] [Full Text] [Related]

  • 32. Hydrocortisone and human lymphocytes: increases in cyclic adenosine 3':5'-monophosphate and potentiation of adenylate cyclase-activating agents.
    Marone G, Lichtenstein LM, Plaut M.
    J Pharmacol Exp Ther; 1980 Nov 15; 215(2):469-78. PubMed ID: 6255128
    [Abstract] [Full Text] [Related]

  • 33. Functional pool of cyclic adenosine 3',5'-monophosphate in rabbit platelets.
    Hashimoto S.
    Thromb Haemost; 1983 Feb 28; 49(1):8-12. PubMed ID: 6302940
    [Abstract] [Full Text] [Related]

  • 34. The effect of a medicinal Chinese herb on platelet function.
    Wang Z, Roberts JM, Grant PG, Colman RW, Schreiber AD.
    Thromb Haemost; 1982 Dec 27; 48(3):301-6. PubMed ID: 6298967
    [Abstract] [Full Text] [Related]

  • 35. Direct inhibitory mechanisms of halothane on human platelet aggregation.
    Kohro S, Yamakage M.
    Anesthesiology; 1996 Jul 27; 85(1):96-106; discussion 30A. PubMed ID: 8694388
    [Abstract] [Full Text] [Related]

  • 36. ADP-dependence of platelet activation induced by a thrombin receptor agonist.
    Savi P, Dol F, Herbert JM.
    Nouv Rev Fr Hematol (1978); 1993 Apr 27; 35(2):115-9. PubMed ID: 8392699
    [Abstract] [Full Text] [Related]

  • 37. [Adenyl cyclase and adenosine-3',5'-monophosphate phosphodiesteraze: their nature, properties and regulation].
    Dumler IL, Etingof RN.
    Vopr Med Khim; 1976 Apr 27; 22(2):151-61. PubMed ID: 16391
    [Abstract] [Full Text] [Related]

  • 38. Developmental pattern of cAMP, adenyl cyclase, and cAMP phosphodiesterase in the palate, lung, and liver of the fetal mouse: alterations resulting from exposure to methylmercury at levels inhibiting palate closure.
    Olson FC, Massaro EJ.
    Teratology; 1980 Oct 27; 22(2):155-66. PubMed ID: 6255623
    [Abstract] [Full Text] [Related]

  • 39. [Role of adenylate cyclase and the mechanism controlling platelet aggregation].
    Yoshida N, Aoki N.
    Rinsho Byori; 1979 Oct 27; Suppl 40():47-53. PubMed ID: 233107
    [No Abstract] [Full Text] [Related]

  • 40. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents.
    Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G.
    Thromb Res; 2004 Oct 27; 114(4):265-73. PubMed ID: 15381390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.